Werbung
Werbung

TVTX

TVTX logo

Travere Therapeutics, Inc. Common Stock

34.58
USD
Gesponsert
-1.02
-2.86%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

34.98

+0.39
+1.14%

TVTX Ergebnisberichte

Positives Überraschungsverhältnis

TVTX übertreffen die 16 der letzten 40Schätzungen.

40%

Nächster Bericht

Datum des nächsten Berichts
18. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
$145.08M
/
-$0.12
Implizierte Änderung von Q3 25 (Revenue/ EPS)
-12.00%
/
-142.86%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
+93.99%
/
-83.56%

Travere Therapeutics, Inc. Common Stock earnings per share and revenue

On 30. Okt. 2025, TVTX reported earnings of 0.28 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 232.08% surprise. Revenue reached 164.86 million, compared to an expected 108.66 million, with a 51.71% difference. The market reacted with a +18.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 145.08 million USD, implying an decrease of -142.86% EPS, and decrease of -12.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Travere Therapeutics, Inc. Common Stock reported EPS of $0.28, beating estimates by 232.08%, and revenue of $164.86M, 51.71% above expectations.
The stock price moved up 18.58%, changed from $29.65 before the earnings release to $35.16 the day after.
The next earning report is scheduled for 18. Feb. 2026.
Based on 16 analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $145.08M for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung